Hepatocellular carcinoma is the most common type of liver cancer. Immunotherapies are established standard of care for advanced cases, though initial approvals were for targeted therapies. Ample development continues for immune modulators across disease stages, both as monotherapy and in combination with other immunotherapies, targeted therapies, novel agents and locoregional therapies.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in hepatocellular carcinoma to help guide strategic and tactical commercial development decisions for market participants.